KRAS and neoplasm: Concerning direct inhibition, the peculiar crystal structure of the KRAS G12C subtype and the unique reactivity of the cysteine thiol result in the ability to covalently bind the cysteine residue within the region adjacent to the nucleotide-binding pocket, inducing a significant perturbation of protein functional domains and a negative allosteric regulation of RAS signaling in tumor cells (56).